Apellis Pharmaceuticals Inc (APLS)

Apr 21, 2025

11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey

Apr 21, 2025

Apr 21, 2025

Craig Wheeler joins Apellis board, brings biopharma expertise By Investing.com - Investing.com South Africa

Apr 21, 2025

Apr 21, 2025

RBC Capital Lowers Price Target on Apellis (APLS) Amid Market Survey Insights | APLS Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Craig Wheeler to Join Apellis Board of Directors - citybiz

Apr 21, 2025

Apr 21, 2025

Apellis Pharmaceuticals appoints new board member - Investing.com Australia

Apr 21, 2025

Apr 21, 2025

Apellis Announces Craig Wheeler To Join The Board Of Directors - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Apellis Pharmaceuticals appoints new board member By Investing.com - Investing.com India

Apr 21, 2025

Apr 21, 2025

Apellis Pharmaceuticals (APLS) Welcomes Craig Wheeler to Board of Directors | APLS Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Apellis Announces Craig Wheeler to Join the Board of Directors | APLS Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Apellis Announces Craig Wheeler to Join the Board of Directors - The Manila Times

Apr 21, 2025

Apr 21, 2025

RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Former Momenta CEO Who Led $13.4B Johnson & Johnson Deal Takes Strategic Role at Apellis - Stock Titan

Apr 21, 2025

Apr 20, 2025

Apellis Pharmaceuticals (APLS) Target Price Reduced by BofA Ahead of Earnings | APLS Stock News - GuruFocus

Apr 20, 2025

Apr 17, 2025

BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating - marketscreener.com

Apr 17, 2025

Apr 15, 2025

Geographic Atrophy Therapeutics Market Size in 7MM is expected - openPR.com

Apr 15, 2025

Apr 15, 2025

Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Pfizer sells site, cuts staff - Fierce Biotech

Apr 15, 2025

Apr 11, 2025

The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26% - simplywall.st

Apr 11, 2025

Apr 05, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Apr 05, 2025

Apr 05, 2025

Apellis Pharma stock hits 52-week low at $21.66 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Apellis Pharma stock hits 52-week low at $21.66 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Apr 03, 2025

Apr 03, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 03, 2025

Apr 03, 2025

Raymond James Financial Inc. Purchases New Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Apr 03, 2025

Apr 02, 2025

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail

Apr 02, 2025

Apr 02, 2025

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag - TradingView

Apr 02, 2025

Apr 02, 2025

Apellis Looks To Unlock Blockbuster Potential For Empaveli, SyfovreOn A Path To Profitability - RTTNews

Apr 02, 2025

Apr 02, 2025

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Apr 02, 2025

Apr 01, 2025

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga

Apr 01, 2025

Apr 01, 2025

Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation - TipRanks

Apr 01, 2025

Apr 01, 2025

Applis wins FDA review to expand Empaveli label (APLS:NASDAQ) - Seeking Alpha

Apr 01, 2025

Apr 01, 2025

Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases - MarketScreener

Apr 01, 2025

Apr 01, 2025

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - The Manila Times

Apr 01, 2025

Apr 01, 2025

Breakthrough: EMPAVELI Scores Priority FDA Review After 68% Disease Reduction in Rare Kidney Disorders - Stock Titan

Apr 01, 2025

Mar 31, 2025

New complement C3 inhibitors disclosed in Apellis patent - BioWorld MedTech

Mar 31, 2025

Mar 29, 2025

(APLS) Investment Analysis - news.stocktradersdaily.com

Mar 29, 2025

Mar 25, 2025

Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com Australia

Mar 25, 2025

Mar 25, 2025

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025

Mar 25, 2025

Apellis Pharma stock hits 52-week low at $23.77 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 24, 2025

12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey

Mar 24, 2025

Mar 24, 2025

Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN

Mar 24, 2025

Mar 24, 2025

Interesting APLS Put And Call Options For May 16th - Nasdaq

Mar 24, 2025

Mar 22, 2025

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli - Yahoo Finance

Mar 22, 2025

Mar 21, 2025

Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail

Mar 21, 2025

Mar 21, 2025

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis - Fierce Pharma

Mar 21, 2025

Mar 20, 2025

Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan

Mar 20, 2025